

Gouri Yogalingam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1904338/publications.pdf>

Version: 2024-02-01

12
papers

472
citations

933447

10
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

647
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. <i>Human Mutation</i> , 2001, 18, 264-281. | 2.5 | 153 |
| 2 | Neuraminidase 1 Is a Negative Regulator of Lysosomal Exocytosis. <i>Developmental Cell</i> , 2008, 15, 74-86. | 7.0 | 136 |
| 3 | Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 6, 43-53. | 4.1 | 34 |
| 4 | Intracerebroventricular enzyme replacement therapy with β -galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice. <i>Journal of Biological Chemistry</i> , 2020, 295, 13532-13555. | 3.4 | 30 |
| 5 | Mucopolysaccharidosis type IIIB: characterisation and expression of wild-type and mutant recombinant β -N-acetylglucosaminidase and relationship with Sanfilippo phenotype in an attenuated patient. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1502, 415-425. | 3.8 | 29 |
| 6 | Mild Feline Mucopolysaccharidosis Type VI. <i>Journal of Biological Chemistry</i> , 1998, 273, 13421-13429. | 3.4 | 18 |
| 7 | BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. <i>PLoS ONE</i> , 2019, 14, e0207836. | 2.5 | 18 |
| 8 | Cellular Uptake and Delivery of Myeloperoxidase to Lysosomes Promote Lipofuscin Degradation and Lysosomal Stress in Retinal Cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 4255-4265. | 3.4 | 17 |
| 9 | Characterization of glycan substrates accumulating in GM1 Gangliosidosis. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 21, 100524. | 1.1 | 15 |
| 10 | Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 14, 56-63. | 4.1 | 12 |
| 11 | Intermittent enzyme replacement therapy with recombinant human β -galactosidase prevents neuraminidase 1 deficiency. <i>Journal of Biological Chemistry</i> , 2020, 295, 13556-13569. | 3.4 | 10 |
| 12 | Aryplase (Biomarin). <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 1111-20. | 2.3 | 0 |